PKI-166|cas:187724-61-4|西域试剂

PKI-166,99.58%

产品编号：Bellancom-117155| CAS NO：187724-61-4| 分子式：C₂₀H₁₈N₄O| 分子量：330.38

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-117155		￥4200.00	杭州北京（现货）
Bellancom-117155		￥6650.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PKI-166

产品介绍

PKI-166 是一种高效、选择性的，有口服生物活性的 EGFR 酪氨酸激酶抑制剂，IC₅₀ 值为 0.7 nM。

生物活性

PKI-166 is a potent, selective and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC₅₀ of 0.7 nM.

体外研究

Pretreatment with PKI-166 (0-0.5 μM; 1 hour) inhibits EGFR autophosphorylation in human pancreatic cancer cells.
PKI-166 (0.03μ M; 6 days) enhanced the cytotoxicity mediated by gemcitabine.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	L3.6pl cells
Concentration:	0.01 μM, 0.05 μM, 0.5 μM
Incubation Time:	1 hour
Result:	Inhibited EGFR autophosphorylation in a dose-dependent manner.

Cell Cytotoxicity Assay

Cell Line:	L3.6pl cells
Concentration:	0.03 μM
Incubation Time:	6 days
Result:	Enhanced the cytotoxicity mediated by gemcitabine.

体内研究
(In Vivo)

PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) inhibits of pancreatic cancer growth.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male athymic nude mice with L3.6pl cells xenograft (8–12 weeks)
Dosage:	100 mg/kg
Administration:	Oral administration; daily; from day 7 to day 35 after xenograft
Result:	Significantly decreased median tumor volume.

体内研究

PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) inhibits of pancreatic cancer growth.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male athymic nude mice with L3.6pl cells xenograft (8–12 weeks)
Dosage:	100 mg/kg
Administration:	Oral administration; daily; from day 7 to day 35 after xenograft
Result:	Significantly decreased median tumor volume.

体内研究

PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) inhibits of pancreatic cancer growth.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male athymic nude mice with L3.6pl cells xenograft (8–12 weeks)
Dosage:	100 mg/kg
Administration:	Oral administration; daily; from day 7 to day 35 after xenograft
Result:	Significantly decreased median tumor volume.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 125 mg/mL (378.35 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.0268 mL	15.1341 mL	30.2682 mL
5 mM	0.6054 mL	3.0268 mL	6.0536 mL
10 mM	0.3027 mL	1.5134 mL	3.0268 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式